Portfolio Companies
We invest in core technologies that can be developed into successful, profitable businesses over time. The EMBL technology portfolio has generated more than 20 companies co-founded by EMBLEM since 1999 and new promising technologies continue to be established.
EMBLEM’s experience in founding new companies and our close working relationship EMBL’s collaboration partners in various industries provide the ideal environment for young start-ups. Please find a selection of our spin-off companies below.
Borea Therapeutics is an innovative biotech start-up located in Milan, and co-founded by Professor Paul Heppenstall and EMBLEM, the technology transfer partner of EMBL (European Molecular Biology Laboratory), and backed…
Umlaut.bio is a preclinical biotech-company targeting the modification of tRNAs for the therapy of cancer and autoimmune diseases. Umlaut.bio GmbH develops first-in-biology small molecules focusing on the “umlauts” of the…
Founded in 2023 by former EMBL scientist Kashif Sadiq, DenovAI Biotech operates at the nexus of artificial intelligence and computational biophysics. DenovAI’s mission is to provide a transformative solution for…
PEPperPRINT is an innovative biotech company founded in 2001. With their proprietary laser printing technology they established the new peptide microarray platform PEPperCHIP – a new standard in peptide microarrays.…